The FDA has approved Uloric (febuxostat, from Takeda) aonce-daily tablet for the chronic management of hyperuricemia in patients withgout. This approval is based on a phase 3 clinical trial demonstrating thatUloric 80mg was superior to Uloric 40mg and allopurinol 300/200mg (67%, 45%, and42%, respectively) at achieving the primary end point of a serum uric acid level<6.0 mg/L at the final visit.

Uloric will be available in 40mg and 80mg dosagestrengths.

For more information call (877) 825-3327 or visit www.uloric.com.